Last reviewed · How we verify
GNR-069
GNR-069 is a small molecule that targets the SGLT2 receptor.
GNR-069 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | GNR-069 |
|---|---|
| Also known as | romiplostim |
| Sponsor | AO GENERIUM |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
GNR-069 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as empagliflozin and canagliflozin.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients (PHASE3)
- Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |